DK2948559T3 - Kv1.3-antagonister og fremgangsmåder til anvendelse - Google Patents
Kv1.3-antagonister og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK2948559T3 DK2948559T3 DK14743871.7T DK14743871T DK2948559T3 DK 2948559 T3 DK2948559 T3 DK 2948559T3 DK 14743871 T DK14743871 T DK 14743871T DK 2948559 T3 DK2948559 T3 DK 2948559T3
- Authority
- DK
- Denmark
- Prior art keywords
- lys
- cys
- pro
- gly
- arg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Insects & Arthropods (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
Claims (15)
1. Isoleret peptidantagonist af Kvi.3 med en aminosyresekvens omfattende en aminosyresekvens der er mindst 84% identisk med SEQ ID NO: 1, yderligere omfattende en substitution af glycin til isoleucin ved position 10 (G10I).
2. Antagonisten ifølge krav 1 hvor: (i) sekvensen omfatter GVPXaaiXaa2VKCXaa3lSRQCXaa4Xaa5PCKDAGMRFGKCMNGKCHCTPK; hvor a) Xaai er I eller T, Q eller E; b) Xaa2 er N eller D; c) Xaa3 er K eller R, E, A eller Q; d) Xaa4 er I, E, L, D, Q, Η, V, K eller A; e) Xaas er E K, L, Q, D, V eller H; og peptidantagonisten af Kvi.3 har en eventuel C-terminal forlængelse på fire aminosyrer; (ii) antagonisten er et fusionsprotein omfattende peptidantagonisten af Kvi.3 konjugeret til en halveringstid-forlængende gruppe, hvor peptidantagonisten af Kvi.3 omfatter sekvensen GVPXaaiXaa2VKCXaa3lSRQCXaa4Xaa5PCKDAGMRFGKCMNGKCHCTPK; hvor a) Xaai er I eller T, Q eller E; b) Xaa2 er N eller D; c) Xaa3 er K eller R, E, A eller Q; d) Xaa4 er I, E, L, D, Q, Η, V, K eller A; e) Xaas er E K, L, Q, D, V eller H; og peptidantagonisten af Kvi.3 har en eventuel C-terminal forlængelse på fire aminosyrer; (iii) sekvensen omfatter GVPXaalXaa2VKCXaa3ISRQCXaa4Xaa5PCKDAGMRFGKCMNGKCHCTPK; hvor a) Xaai er I eller T b) Xaa2 er N eller D; c) Xaa3 er K eller R; d) Xaa4 er I eller E; e) Xaa5 er E eller K; og peptidantagonisten af Kvi.3 har en eventuel C-terminal forlængelse på fire aminosyrer; og/eller iv) peptidantagonisten af Kvi.3 omfatter aminosyresekvensen af SEQ ID NO: 42, 3, 13, 21, 22, 24, 26, 29, 30, 32, 34, 38, 39, 43, 44, 45, 46, 49, 51, 59, 63, 65, 69, 71, 73, 76, 78, 81, 82, 83, 85, 87, 89, 92, 96, 101, 103, 104, and 108, eventuelt hvor peptidantagonisten af Kvi.3 omfatter aminosyresekvensen af SEQ ID NO: 3, 22, 34 eller 42.
3. Antagonisten ifølge krav 1 eller krav 2, hvor: (i) den C-terminale forlængelse omfatter aminosyresekvensen af SEQ ID NO: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267 eller 268, eventuelt hvor den C-terminale forlængelse omfatter aminosyresekvensen af SEQ ID NO: 128, 143, 155, 188, 206-210, 212, 214, 216, 219, 223, 224, 227, 230, 232 -235, 237, 239, 240, 243, 252, 261, 262, 263, eller 268; og/eller (ii) den halveringstid-forlængende gruppe er humant serumalbumin, albumin bindende domæne(ADB), eller polyethylene glycol (PEG), eventuelt hvor den halveringstid-forlængende gruppe er humant serumalbumin.
4. Antagonisten ifølge kravene 1-3, hvor den halveringstid-forlængende gruppe er konjugeret til peptidantagonisten af Kvi.3 via en linker, eventuelt hvor linkeren aminosyresekvensen af SEQ ID NO: 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 eller 428.
5. Antagonisten ifølge krav 4, hvor (i) a) peptidantagonisten af Kvi.3 omfatter aminosyresekvensen af SEQ ID NO: 3, 22, 34 eller 42; b) eventuelt omfatter den C-terminale forlængelse aminosyresekvensen af SEQ ID NO: 128, 143, 155, 188, 206- 210, 212, 214, 216, 219, 223, 224, 227, 230, 232 -235, 237, 239, 240, 243, 252, 261, 262, 263, eller 268; c) linkeren omfatter aminosyresekvensen af SEQ ID NO: 116 eller SEQ ID NO: 119; og d) den halveringstid-forlængende gruppe er humant serumalbumin; (ii) a) peptidantagonisten af Kvi.3 omfatter aminosyresekvensen af SEQ ID NO: 42; b) linkeren omfatter aminosyresekvensen af SEQ ID NO: 116; og c) den halveringstid-forlængende gruppe er humant serumalbumin; (iii) a) peptidantagonisten af Kvi.3 omfatter aminosyresekvensen af SEQ ID NO: 42; b) den C-terminale forlængelse omfatter aminosyresekvensen af SEQ ID NO: 209; c) linkeren omfatter aminosyresekvensen af SEQ ID NO: 116; og d) den halveringstid-forlængende gruppe er humant serumalbumin; (iv) a) peptidantagonisten af Kvi.3 omfatter aminosyresekvensen af SEQ ID NO: 3; b) den C-terminale forlængelse omfatter aminosyresekvensen af SEQ ID NO: 235; c) linkeren omfatter aminosyresekvensen af SEQ ID NO: 116; og d) den halveringstid-forlængende gruppe er humant serumalbumin; eller (v) a) peptidantagonisten af Kvi.3 omfatter aminosyresekvensen af SEQ ID NO: 42; b) den C-terminale forlængelse omfatter aminosyresekvensen af SEQ ID NO: 235; c) linkeren omfatter aminosyresekvensen af SEQ ID NO: 116; og d) den halveringstid-forlængende gruppe er humant serumalbumin.
6. Antagonisten ifølge kravene 2-5, hvor antagonisten er mindst 100 gange mere selektiv mod humant Kvi.3 end mod humant Kvl.l, når selektivitet er målt som et forhold på en ICso-værdi af det isolerede fusionsprotein for Kvl.l til en ICso-værdi af det isolerede fusionsprotein for Kvi.3 I et patch clamp assay i celler transfekteret med respektivt Kvl.l og Kvi.3; eventuelt hvor antagonisten inhiberer kaliumstrømme med en ICso-værdi mindst ca. 10 gange mindre end en IC5o-værdi for et moder-KVlC2-fusionsprotein af SEQ ID NO: 425 i et patch clamp assay i celler transfekteret med human Kvi.3; fortrinsvis hvor fusionsprotinet inhiberer strømme med en ICso-værdi på ca. I,5xl0'8 M eller derunder i et patch clamp assay i celler transfekteret med humant Kvi.3; eventuelt hvor fusionsproteinet inhiberer in vitro thallium flux med en ICso-værdi på ca. 2,2xl0'8 M eller derunder i celler transfekteret med humant Kvi.3.
7. Antagonisten ifølge krav 1 omfattende sekvensen ifølge et hvilket som helst af SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109 eller 110.
8. Antagonisten ifølge krav 7, hvor antagonisten er et fusionsprotein omfattende en peptidantagonist af Kvi.3 konjugeret til en halveringstid-forlængende gruppe via en linker, peptidantagonisten af Kvi.3 med en eventuelt C-terminal forlængelse på fire aminosyrer, hvor a) peptidantagonisten af Kvi.3 omfatter aminosyresekvensen af SEQ ID NO: 3-54, 56-83, 85 eller 87-110; b) den C-terminale forlængelse omfatter aminosyresekvensen af SEQ ID NO: 123-268; c) linkeren omfatter aminosyresekvensen af SEQ ID NO: 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 eller 428; og d) den halveringstid-forlængende gruppe er humant serumalbumin.
9. Isoleret polynukleotid der koder for antagonisten ifølge et hvilket som helst af de foregående krav.
10. Vektor omfattende det isolerede polynukleotid ifølge krav 9.
11. Værtscelle omfattende en vektor ifølge krav 10.
12. Fremgangsmåde til fremstilling af den isolerede antagonist ifølge kravene 1-7, omfattende dyrkning af værtscellen ifølge krav 11 og genvinde antagonisten udtrykt af værtscellen.
13. Farmaceutisk sammensætning omfattende antagonisten ifølge kravene 1-7 og en farmaceutisk acceptabel bærer.
14. Antagonisten ifølge kravene 1-7 til anvendelse i en fremgangsmåde til at undertrykke T-celleaktivering hos et individ med en tilstand associeret med uønsket T-celleaktivering, eventuelt hvor tilstanden associeret med uønsket T-celleaktivering er en inflammatorisk tilstand, en immun- og proliferativ sygdom, rheumatoid arthritis (RA), ankylosing spondylitis, psoriatrisk arthritis, osteoarthritis, osteoporosis, uveitis, inflammatorisk fibrose, scleroderma, lungafibrose, cirrhose, inflammatorisk tarmsygdom, Crohn's sygdom, ulcerativ colitis, astma, allergisk astma, allergier, Kronisk obstruktive pulmonære sygdomme (COPD), multipel sclerose, psoriasis, kontact-medieret dermatitis, systemisk lupus erythematosus (SLE) og andre former af lupus, diabetes, type I diabetes, obesity, cancer, lupus, restenosis, systemic sclerosis, scleroderma, glomerulonephritis, Sjogren syndrom, inflammatorisk knogleresorption, transplantatafstødning, eller graft-versus-host sygdom.
15. Antagonisten ifølge kravene 1-7 til anvendelse i terapi.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756777P | 2013-01-25 | 2013-01-25 | |
| US201361757389P | 2013-01-28 | 2013-01-28 | |
| PCT/US2014/012932 WO2014116937A1 (en) | 2013-01-25 | 2014-01-24 | Kv1.3 antagonists and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2948559T3 true DK2948559T3 (da) | 2018-05-28 |
Family
ID=51228060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14743871.7T DK2948559T3 (da) | 2013-01-25 | 2014-01-24 | Kv1.3-antagonister og fremgangsmåder til anvendelse |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10179808B2 (da) |
| EP (1) | EP2948559B1 (da) |
| JP (1) | JP6469590B2 (da) |
| KR (1) | KR102268830B1 (da) |
| CN (1) | CN104937105A (da) |
| AU (1) | AU2014209227B2 (da) |
| BR (1) | BR112015017795A2 (da) |
| CA (1) | CA2898496A1 (da) |
| CY (1) | CY1120481T1 (da) |
| DK (1) | DK2948559T3 (da) |
| EA (1) | EA037308B1 (da) |
| ES (1) | ES2671434T3 (da) |
| HR (1) | HRP20181055T1 (da) |
| HU (1) | HUE039465T2 (da) |
| IL (1) | IL239927B (da) |
| LT (1) | LT2948559T (da) |
| MX (1) | MX365987B (da) |
| NZ (1) | NZ709913A (da) |
| PH (1) | PH12015501627B1 (da) |
| PL (1) | PL2948559T3 (da) |
| PT (1) | PT2948559T (da) |
| RS (1) | RS57422B1 (da) |
| SG (1) | SG11201505508TA (da) |
| SI (1) | SI2948559T1 (da) |
| SM (1) | SMT201800357T1 (da) |
| TR (1) | TR201809377T4 (da) |
| UA (1) | UA117824C2 (da) |
| WO (1) | WO2014116937A1 (da) |
| ZA (1) | ZA201506131B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3180365B1 (en) * | 2014-08-15 | 2021-08-18 | Monash University | Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases |
| CN107530887B (zh) | 2015-03-05 | 2020-11-20 | 哈佛大学董事会 | 机器人抓握器、联动装置及用于机器人抓握的方法 |
| CA3022961A1 (en) * | 2016-05-02 | 2017-11-09 | Tetragenetics, Inc. | Anti-kv1.3 antibodies, and methods of production and use thereof |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| TW201808987A (zh) * | 2016-06-08 | 2018-03-16 | 健生生物科技公司 | Ｇｍ－ｃｓｆ變體及使用方法 |
| CN106589092A (zh) * | 2016-12-22 | 2017-04-26 | 中国科学技术大学先进技术研究院 | 一种蝎毒素多肽及制备拥有类似天然生理功能的蝎毒素多肽的方法 |
| CN106957357B (zh) * | 2017-04-01 | 2021-02-19 | 合肥科生景肽生物科技有限公司 | 一种蝎毒素多肽及其合成方法 |
| EA202191105A1 (ru) | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| CA3155089A1 (en) * | 2019-09-20 | 2021-03-25 | Zealand Pharma A/S | Kv1.3 blockers |
| US20240182531A1 (en) | 2021-03-23 | 2024-06-06 | Zealand Pharma A/S | KV1.3 Blockers |
| JP2025534884A (ja) | 2022-10-18 | 2025-10-20 | ジーランド ファーマ エー／エス | 阻害剤 |
| WO2026003546A1 (en) | 2024-06-27 | 2026-01-02 | Vrg Miniprotein Zrt | Potassium ion kv1.3 channel inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| PT1015576E (pt) | 1997-09-16 | 2005-09-30 | Egea Biosciences Llc | Metodo para a sintese quimica completa e montagem de genes e de genomas |
| GB0414272D0 (en) * | 2004-06-25 | 2004-07-28 | Cellpep Sa | OsK1 derivatives |
| AU2005294124B2 (en) | 2004-10-07 | 2012-02-23 | Bachem Biosciences, Inc. | Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| PE20081140A1 (es) | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| EP2229473A4 (en) | 2007-12-07 | 2011-02-02 | Steven A Goldstein | IDENTIFICATION OF TOXIN LIGANDS |
| US20110236461A1 (en) * | 2008-08-13 | 2011-09-29 | Underhill T Michael | Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor |
| CA2755336C (en) | 2009-03-20 | 2015-07-14 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
-
2014
- 2014-01-24 LT LTEP14743871.7T patent/LT2948559T/lt unknown
- 2014-01-24 CA CA2898496A patent/CA2898496A1/en not_active Abandoned
- 2014-01-24 JP JP2015555340A patent/JP6469590B2/ja not_active Expired - Fee Related
- 2014-01-24 SG SG11201505508TA patent/SG11201505508TA/en unknown
- 2014-01-24 TR TR2018/09377T patent/TR201809377T4/tr unknown
- 2014-01-24 RS RS20180808A patent/RS57422B1/sr unknown
- 2014-01-24 US US14/163,158 patent/US10179808B2/en not_active Expired - Fee Related
- 2014-01-24 PT PT147438717T patent/PT2948559T/pt unknown
- 2014-01-24 EA EA201591380A patent/EA037308B1/ru unknown
- 2014-01-24 UA UAA201508231A patent/UA117824C2/uk unknown
- 2014-01-24 DK DK14743871.7T patent/DK2948559T3/da active
- 2014-01-24 BR BR112015017795A patent/BR112015017795A2/pt not_active IP Right Cessation
- 2014-01-24 EP EP14743871.7A patent/EP2948559B1/en active Active
- 2014-01-24 MX MX2015009632A patent/MX365987B/es active IP Right Grant
- 2014-01-24 SM SM20180357T patent/SMT201800357T1/it unknown
- 2014-01-24 HR HRP20181055TT patent/HRP20181055T1/hr unknown
- 2014-01-24 PL PL14743871T patent/PL2948559T3/pl unknown
- 2014-01-24 HU HUE14743871A patent/HUE039465T2/hu unknown
- 2014-01-24 WO PCT/US2014/012932 patent/WO2014116937A1/en not_active Ceased
- 2014-01-24 CN CN201480006077.8A patent/CN104937105A/zh active Pending
- 2014-01-24 AU AU2014209227A patent/AU2014209227B2/en not_active Ceased
- 2014-01-24 SI SI201430719T patent/SI2948559T1/en unknown
- 2014-01-24 ES ES14743871T patent/ES2671434T3/es active Active
- 2014-01-24 KR KR1020157022631A patent/KR102268830B1/ko not_active Expired - Fee Related
- 2014-01-24 NZ NZ709913A patent/NZ709913A/en not_active IP Right Cessation
-
2015
- 2015-07-14 IL IL239927A patent/IL239927B/en active IP Right Grant
- 2015-07-23 PH PH12015501627A patent/PH12015501627B1/en unknown
- 2015-08-24 ZA ZA2015/06131A patent/ZA201506131B/en unknown
-
2018
- 2018-07-31 CY CY20181100787T patent/CY1120481T1/el unknown
- 2018-09-07 US US16/124,295 patent/US20190062383A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2948559T3 (da) | Kv1.3-antagonister og fremgangsmåder til anvendelse | |
| US11919931B2 (en) | Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3) | |
| IL293698A (en) | Recombinant peptide-mhc complex binding proteins, their production and use | |
| JP7225116B2 (ja) | Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン | |
| JP2022008319A (ja) | プロトキシン－ｉｉ変異体及びその使用方法 | |
| JP6985151B2 (ja) | プロトキシン−ｉｉ変異体及びその使用方法 | |
| Edwards et al. | Targeting the ion channel Kv1. 3 with scorpion venom peptides engineered for potency, selectivity, and half-life | |
| CA3000697A1 (en) | Treatment of bile acid disorders | |
| KR102352336B1 (ko) | 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 융합단백질 및 이의 용도 | |
| AU2008256550B2 (en) | VEGF-D mutants and their use | |
| CN115702169A (zh) | 包含促红细胞生成素多肽的融合蛋白 | |
| RU2836280C1 (ru) | Слитый белок gdf15 длительного действия и содержащая его фармацевтическая композиция | |
| US20040053249A1 (en) | Fas ligand-fused proteins |